Overview

A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma

Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This study is a single arm, non-randomized, open label phase 2 international, multicenter clinical trial to evaluate preliminary efficacy and safety in subjects with relapsed or refractory lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Mabwell (Shanghai) Bioscience Co., Ltd.